Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression

30 Aug 2023

Abstract excerpt

Depression is a global mental health concern, and personalized treatment approaches are needed to optimize its management. This study aimed to investigate the influence of the CYP2D6 and CYP1A2 gene polymorphisms on the efficacy of duloxetine in reducing depressive and anxiety symptoms. A sample of 100 outpatients with major depression, who initiated monotherapy with duloxetine, were followed up. Polymorphisms in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mental Health Research Topics
Share to Treatment of Major Depression
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37686266
DOI: 10.3390/ijms241713459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major DepressionPMID 37686266Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Effect of CYP2D6 genotype on duloxetine serum concentration.Semantic proximity Read ↗

The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort studySemantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

[Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].Semantic proximity Read ↗

Pharmacogenomic profiling of CYP2D6 and CYP2C19 in Indian psychiatric patientsSemantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.